Fibrosis-Inflammation Lab

⌘K

Fibrosis-Inflammation Lab

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights
Resources
Pathways

Company

About
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

/

/

CCl4-Induced Liver Fibrosis | Accelerate Your Fibrosis Research

Home/Models/CCl4-Induced Liver Fibrosis

CCl4-Induced Liver Fibrosis

chemicalfibrosisliver

Species

Rat

Duration

Protocol ID

M-cG9zdDoyMjg=

Model Overview

Classic model for hepatic fibrosis induced by carbon tetrachloride.

Methodology

Key Endpoints

Sirius red staining
Serum liver enzymes
Fibrosis markers

Relevant Publications

Diosgenin alleviates hepatic fibrosis via PI3K/Akt/mTOR mediated fatty acid metabolic reprogramming and NF-κB activation.

Shi Y, Zhang Y, Liu D et al.

J Ethnopharmacol2026 Apr 29

A Novel Anti-Fibrotic Role of G-Protein-Coupled Receptor 119 in Hepatic Stellate Cells.

Park J, Lee MH, Kim HY et al.

Biomol Ther (Seoul)2026 May 1

CRISPLD2 protects against liver inflammation and fibrosis via GRP78 to repress HMGB1/TLR4 axis-mediated STING palmitoylation.

Zhang H, Wang J, Yang H et al.

Hepatol Commun2026 May 1

Longchai Decoction Treated the Fibrosis of Liver Induced by CCl(4) Regulates Nrf2/GPX4 Pathway to Suppress Ferroptosis.

Wang H, Wang L, Zhu F et al.

J Cell Mol Med2026 Apr

Saikosaponin B1 alleviates hepatic fibrosis by targeting the LDHA-MCT1/4 axis to inhibit lactate-driven profibrogenic signaling.

Wang G, Jiang H, Li N et al.

Naunyn Schmiedebergs Arch Pharmacol2026 Apr 21

View more on PubMed

Related Drugs

Resmetirom (Rezdiffra)

resmetirom